<SEC-DOCUMENT>0001104659-23-080099.txt : 20230711
<SEC-HEADER>0001104659-23-080099.hdr.sgml : 20230711
<ACCEPTANCE-DATETIME>20230711203026
ACCESSION NUMBER:		0001104659-23-080099
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20230707
FILED AS OF DATE:		20230711
DATE AS OF CHANGE:		20230711

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Deliargyris Efthymios
		CENTRAL INDEX KEY:			0001751617

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36792
		FILM NUMBER:		231083088

	MAIL ADDRESS:	
		STREET 1:		C/O PLX PHARMA,INC.8285 EL RIO STREET
		STREET 2:		SUITE 210
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77054

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cytosorbents Corp
		CENTRAL INDEX KEY:			0001175151
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				980373793
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		305 COLLEGE ROAD EAST
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540
		BUSINESS PHONE:		973-329-8885

	MAIL ADDRESS:	
		STREET 1:		305 COLLEGE ROAD EAST
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MedaSorb Technologies CORP
		DATE OF NAME CHANGE:	20060807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GILDER ENTERPRISES INC
		DATE OF NAME CHANGE:	20020611
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>tm2321021-1_4seq1.xml
<DESCRIPTION>OWNERSHIP DOCUMENT
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0407</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2023-07-07</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001175151</issuerCik>
        <issuerName>Cytosorbents Corp</issuerName>
        <issuerTradingSymbol>CTSO</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001751617</rptOwnerCik>
            <rptOwnerName>Deliargyris Efthymios</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O CYTOSORBENTS CORPORATION</rptOwnerStreet1>
            <rptOwnerStreet2>305 COLLEGE ROAD EAST</rptOwnerStreet2>
            <rptOwnerCity>PRINCETON</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>08540</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Chief Medical Officer</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2023-07-07</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>55000</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>331648</value>
                    <footnoteId id="F2"/>
                    <footnoteId id="F3"/>
                    <footnoteId id="F4"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>3.53</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2023-07-07</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>78000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F5"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-07-07</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>78000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>78000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>3.53</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2023-07-07</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>40000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F6"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-07-07</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>40000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>40000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">These shares represent restricted stock units (&quot;RSUs&quot;) which shall vest as to two-thirds of the award on the first anniversary of the date of grant and one-third of the award on the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.</footnote>
        <footnote id="F2">Includes (a) (i) 120,000 RSUs granted on April 9, 2020 that will be settled into Common Stock upon vesting upon a &quot;Change In Control&quot; of CytoSorbents Corporation (the &quot;Company&quot;) as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the &quot;Plan&quot;);</footnote>
        <footnote id="F3">(continued from footnote 2) (b) the following RSUs: (a) 20,000 RSUs granted on April 9, 2020 and unvested on the date hereof (these RSUs cliff vest on the fourth anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date); (b) 55,000 RSUs granted on August 10, 2022 and unvested on the date hereof (these RSUs vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date); and (c) 55,000 RSUs granted on July 7, 2023 and reported on this Form 4; and</footnote>
        <footnote id="F4">(continued from footnote 3) (c) 46,981 shares of Common Stock owned by the reporting person.</footnote>
        <footnote id="F5">These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on the first anniversary of the date of grant, one-fourth of the award on the second anniversary of the date of grant, and onefourth of the award on the third anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.</footnote>
        <footnote id="F6">These stock options were granted pursuant to the Plan. The shares underlying these stock options vest as to one-half of the award on each of the first anniversary of the date of grant and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Kathleen P. Bloch attorney-in-fact for Efthymios Deliargyris</signatureName>
        <signatureDate>2023-07-11</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
